Molecular endocrinology and principles of diabetes therapeutics: application to ultra-stable insulin analogs

分子内分泌学和糖尿病治疗原理:超稳定胰岛素类似物的应用

基本信息

项目摘要

Insulin plays a central role in the treatment of diabetes mellitus (DM). If feasible at the molecular level, ultra-stable insulin analogs could (a) enhance the safety of intraperitoneal pumps for the treatment of Type 1 DM and (b) facilitate global distribution of insulin formulations for the treatment of Type 1 and Type 2 DM. This proposal, in a nutshell, seeks to translate molecular insights to obtain ultra-stable therapeutic insulin analogs. Our approach focuses on the structure and function of ultra-stable single-chain insulin (SCI) analogs. SCIs, containing a shortened connecting peptide (“C domain”) between A- and B chains, also provide unique probes of structure-activity relationships. Protein design rests upon two premises: Hypothesis 1: That the SCI framework provides a “sweet spot” for design of C domains: long enough to enable induced fit on receptor binding yet incompatible with amyloid-associated thermal inactivation. Hypothesis 2: That SCIs can be made ultra-stable via sequence features of the A, B and C domains to damp conformational fluctuations in the free protein and yet permit native biological activity. The proposed studies will provide design rules for clinical translation. Our preliminary results suggest that SCIs can provide a platform for all 3 therapeutic forms of insulin: rapid-acting (prandial), long-acting (basal) and biphasic (pre-mixed) formulations. Attention will be paid to cell-specific signaling properties, including potential mitogenicity relative to WT human insulin and carcinogenic analog X10 (AspB10-insulin). The essential idea underlying our SCI strategy exploits a conformational switch between a closed state of the hormone (as observed in classical structures of insulin) and an open state (as observed on binding of the hormone to a model IR fragment complex; designated the “micro-receptor” (µIR)). Our strategy and its feasibility are described in two recent back-to-back publications: Glidden, M.D., et al. J. Biol. Chem. 293, 47-68 and 69-88 (2018ab). Methods are described in detail in these articles and their web-based Supplements. Protein design will be based both on classical insulin crystal structures (Adams, M.J., et al. Nature (1969) 224, 491-5) and on recent advances in the structural dissection of the insulin receptor (IR) and its mode of hormone binding [Menting, J.G., et al. Nature (2013) 493, 241-5, and PNAS-Plus (2014) 111, E3395-404], with innovation enhanced via cryo-EM structures of the intact ectodomain containing insulin bound in its signaling conformation [Weis, F., et al. Nature Commun. (2018) 9, 4420]. The Research plan thus exploits the ongoing cryo-EM “resolution revolution” via Subcontract to M.C. Lawrence. An interdisciplinary Approach is proposed by a unique team with integrated MPI Management Plan and Internal Advisory Committee. The significance and innovation are described by American Diabetes Association President Dr. L. Philipson (University of Chicago; letter attached).
胰岛素在糖尿病(DM)的治疗中起着核心作用。如果在分子水平上可行,超稳定的胰岛素类似物可以(a)提高治疗1型糖尿病的腹腔泵的安全性,(b)促进治疗1型和2型糖尿病的胰岛素配方的全球分布。简而言之,该建议寻求转化分子见解以获得超稳定的治疗性胰岛素类似物。我们的方法侧重于超稳定单链胰岛素(SCI)类似物的结构和功能。SCIs在a链和B链之间含有一个缩短的连接肽(“C结构域”),也提供了独特的结构-活性关系探针。蛋白质设计基于两个前提:假设1:SCI框架为C结构域的设计提供了一个“最佳点”:足够长,可以诱导适合受体结合,但与淀粉样蛋白相关的热失活不相容。假设2:SCIs可以通过A, B和C结构域的序列特征来抑制游离蛋白的构象波动,同时允许天然生物活性。提出的研究将为临床翻译提供设计规则。我们的初步结果表明,SCIs可以为所有3种治疗形式的胰岛素提供一个平台:速效(膳食)、长效(基础)和双相(预混合)配方。将关注细胞特异性信号特性,包括与WT人胰岛素和致癌类似物X10 (aspb10 -胰岛素)相关的潜在有丝分裂性。我们的SCI策略的基本思想是利用激素的封闭状态(如在胰岛素的经典结构中观察到的)和开放状态(如在激素与模型IR片段复合物结合时观察到的,称为“微受体”(µIR))之间的构象转换。我们的策略及其可行性在最近的两篇背靠背的出版物中进行了描述:Glidden, m.d.等。生物。化学,293,47 -68和69-88 (2018ab)。在这些文章及其基于web的补充中详细描述了方法。蛋白质设计将基于经典的胰岛素晶体结构(Adams, m.j.等)。Nature(1969) 224, 491-5)和胰岛素受体(IR)结构解剖及其激素结合模式的最新进展[ming, J.G., et al.]。Nature (2013) 493, 241-5, and PNAS-Plus (2014) 111, E3395-404],通过冷冻电镜结构增强了包含胰岛素结合信号构象的完整外结构域的创新[Weis, F.,等。]Commun性质。(2018) 9,4420]。研究计划因此利用正在进行的低温电镜“分辨率革命”通过分包给M.C.劳伦斯。跨学科的方法是由一个独特的团队与综合MPI管理计划和内部咨询委员会提出的。美国糖尿病协会主席L. Philipson博士(芝加哥大学,附信)描述了这项研究的意义和创新。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Single-chain insulin analogs threaded by the insulin receptor αCT domain.
单链胰岛素类似物由胰岛素受体αCT结构域连接。
  • DOI:
    10.1016/j.bpj.2022.09.038
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    3.4
  • 作者:
    Smith,NicholasA;Menting,JohnG;Weiss,MichaelA;Lawrence,MichaelC;Smith,BrianJ
  • 通讯作者:
    Smith,BrianJ
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Millie M Georgiadis其他文献

Millie M Georgiadis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Millie M Georgiadis', 18)}}的其他基金

INTERACTIONS OF APE1 AND C-JUN WITH E3330
APE1 和 C-JUN 与 E3330 的相互作用
  • 批准号:
    8361352
  • 财政年份:
    2011
  • 资助金额:
    $ 61.97万
  • 项目类别:
INTERACTIONS OF APE1 AND C-JUN WITH E3330
APE1 和 C-JUN 与 E3330 的相互作用
  • 批准号:
    8168702
  • 财政年份:
    2010
  • 资助金额:
    $ 61.97万
  • 项目类别:
INTERACTIONS OF APE1 AND C-JUN WITH E3330
APE1 和 C-JUN 与 E3330 的相互作用
  • 批准号:
    7953914
  • 财政年份:
    2009
  • 资助金额:
    $ 61.97万
  • 项目类别:
INTERACTIONS OF APE1 AND C-JUN WITH E3330
APE1 和 C-JUN 与 E3330 的相互作用
  • 批准号:
    7721477
  • 财政年份:
    2008
  • 资助金额:
    $ 61.97万
  • 项目类别:
Mechanism of Redox Regulation by Ape1/Ref-1
Ape1/Ref-1 的氧化还原调节机制
  • 批准号:
    7806505
  • 财政年份:
    2006
  • 资助金额:
    $ 61.97万
  • 项目类别:
Mechanism of Redox Regulation by Ape1/Ref-1
Ape1/Ref-1 的氧化还原调节机制
  • 批准号:
    7424924
  • 财政年份:
    2006
  • 资助金额:
    $ 61.97万
  • 项目类别:
Mechanism of Redox Regulation by Ape1/Ref-1
Ape1/Ref-1 的氧化还原调节机制
  • 批准号:
    7144509
  • 财政年份:
    2006
  • 资助金额:
    $ 61.97万
  • 项目类别:
Mechanism of Redox Regulation by Ape1/Ref-1
Ape1/Ref-1 的氧化还原调节机制
  • 批准号:
    7616748
  • 财政年份:
    2006
  • 资助金额:
    $ 61.97万
  • 项目类别:
INTERACTIONS OF APE1 TO C-JUN OR E3330
APE1 与 C-JUN 或 E3330 的相互作用
  • 批准号:
    7355301
  • 财政年份:
    2006
  • 资助金额:
    $ 61.97万
  • 项目类别:
Mechanism of Redox Regulation by Ape1/Ref-1
Ape1/Ref-1 的氧化还原调节机制
  • 批准号:
    7254734
  • 财政年份:
    2006
  • 资助金额:
    $ 61.97万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 61.97万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.97万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 61.97万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.97万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 61.97万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 61.97万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.97万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 61.97万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 61.97万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.97万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了